Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Prescient Therapeutics Limited ( (AU:PTX) ) is now available.
Prescient Therapeutics Limited announced the cessation of 1,950,000 securities due to the expiry of options without exercise or conversion, effective July 7, 2025. This development reflects a routine adjustment in the company’s issued capital, which may impact stakeholders’ perceptions of the company’s financial strategy and market positioning.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on developing innovative cancer therapies. The company is primarily engaged in creating targeted and personalized medicine solutions to improve cancer treatment outcomes.
Average Trading Volume: 919,165
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$33.82M
For a thorough assessment of PTX stock, go to TipRanks’ Stock Analysis page.